Aljian Capital Management’s AbbVie ABBV Stock Holding History

Aljian Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.77M	Buy	7,024 +24	+0.3%	+$5.16K	0.33%	44
2026 Q1	$1.52M	Buy	7,000 +914	+15%	+$203K	0.31%	46
2025 Q4	$1.39M	Sell	6,086 -224	-4%	-$51K	0.28%	47
2025 Q3	$1.46M	Sell	6,310 -16	-0.3%	-$3.26K	0.29%	47
2025 Q2	$1.17M	Sell	6,326 -377	-6%	-$70.1K	0.26%	52
2025 Q1	$1.4M	Sell	6,703 -18	-0.3%	-$3.5K	0.33%	40
2024 Q4	$1.19M	Sell	6,721 -7	-0.1%	-$1.29K	0.26%	42
2024 Q3	$1.33M	Buy	+6,728	New	+$1.26M	0.31%	40
2019 Q3	–	Sell	-2,788	Closed	-$203K	–	49
2019 Q2	$203K	Sell	2,788 -325	-10%	-$25.5K	0.17%	53
2019 Q1	$251K	Sell	3,113 -690	-18%	-$56.4K	0.21%	47
2018 Q4	$351K	Buy	+3,803	New	+$334K	0.35%	40

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aljian Capital Management's ABBV Position: Q2 2026 in Review

Aljian Capital Management increased its AbbVie (ABBV) stake by 0.34% in Q2 2026, buying an estimated $5.16K and bringing the position to 7,024 shares worth $1.77M. The position accounts for 0.33% of the portfolio, ranked #44.

Aljian Capital Management first reported a position in ABBV in Q4 2018 and has held it in 11 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Aljian Capital Management held 7,024 shares of AbbVie worth $1.77M as of Q2 2026.
Aljian Capital Management bought 24 AbbVie shares in Q2 2026, an estimated $5.16K.
AbbVie made up 0.33% of Aljian Capital Management's portfolio in Q2 2026, its #44 holding.
Aljian Capital Management first reported a position in AbbVie in Q4 2018 and has held it in 11 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Aljian Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.